May 21, 2020 / 11:23 AM / 4 days ago

BRIEF-Apellis Plans To Submit NDA For Pegcetacoplan In Paroxysmal Nocturnal Hemoglobinuria

May 21 (Reuters) - Apellis Pharmaceuticals Inc:

* APELLIS ANNOUNCES PLANS TO SUBMIT NDA FOR PEGCETACOPLAN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

* APELLIS PHARMACEUTICALS INC - SUBMISSION OF NEW DRUG APPLICATION (NDA) PLANNED FOR SECOND HALF OF 2020 FOLLOWING SUCCESSFUL PRE-NDA MEETING WITH FDA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below